About Cellulac
Cellulac is a Healthcare company based in London (United Kingdom) founded in 2009, and was acquired by Integumen in April 2018. Bioprocess technologies for biofuels and biochemicals are commercialized. The company has 2 employees. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is CELLULAC PLC.
Company details
Cellulac is an industrial biotechnology company that acquires or licenses bioprocess technologies for the production of valuable products such as biofuels, solvents and omega-3 dietary supplements. The company specializes in recovering significant value from undervalued assets by integrating biological and engineering efficiencies to create bioprocesses with reduced costs and improved margins, for the production of biofuels and biochemicals. The technology platforms and processes currently being commercialized by the company include Bioplastics Solutions (a vertically integrated waste management solution for hospitals using biodegradable hospital consumables, in a closed, carbon-neutral loop from production to disposal), Cellulac Cellulosic ethanol plant (for the production of ethanol, in addition to other valuable products such as ethyl lactate, sodium bicarbonate, lactic acid, biogas, plant proteins etc.), algae wet recovery technology (for efficient recovery of algal lipids), etc. Most of Cellulacs bioprocesses are enabled by their proprietary SoniqueFlo technology that uses a supersonic controllable shockwave formed from the forced flow of steam or gas into a specially shaped chamber. The unique design features and capabilities of the SoniqueFlo system allow the use of 2nd and 3rd generation feedstocks for the energy-efficient production of commercial quantities of C5 and C6 sugars. The company is also part of collaborations and consortia for development of various products and technologies, such as SPLASH and FUEL4ME - EU projects for developing biobased production platforms using algae, AlgaePARC (an industry consortium for development of algal biodiesel), ALGZYM (an EU project for commercialization of a green enzyme technology for omega-3 oil production from algae).
- Headquarters London, United Kingdom
- Employees 2
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website cellulac.com
- Social LinkedIn X Facebook
- Acquired by Integumen (Apr 2018)
- Legal Name Cellulac Plc
- Date of Incorporation 26 Jul, 2013
- Jurisdiction LONDON, ENGLAND
Investors in Cellulac
Cellulac has secured backing from 1 investor. Prominent investors backing the company include Integumen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Develops innovative technologies for skincare and wound dressing products. | 2017 | integumen.com | Dublin, Ireland |
Investor details for Cellulac
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cellulac
1 people are tracked at Cellulac (1 in leadership); the tracked headcount is 2.
| Name | Role | Group |
|---|---|---|
Gerard Brandon | Chief Executive Officer | Leadership |
Complete people profiles for Cellulac
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cellulac
2 dated milestones of Cellulac across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Cellulac is founded.
- Exit Acquired by Integumen.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Cellulac (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cellulac
Complete news archive for Cellulac
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellulac
Cellulac was founded in 2009.
Cellulac is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Cellulac has 2 employees.
Cellulac is an industrial biotechnology company that acquires or licenses bioprocess technologies for the production of valuable products such as biofuels, solvents and omega-3 dietary supplements. The company specializes in recovering significant value from undervalued assets by integrating biological and engineering efficiencies to create bioprocesses with reduced costs and improved margins, for the production of biofuels and biochemicals. The technology platforms and processes currently being commercialized by the company include Bioplastics Solutions (a vertically integrated waste management solution for hospitals using biodegradable hospital consumables, in a closed, carbon-neutral loop from production to disposal), Cellulac Cellulosic ethanol plant (for the production of ethanol, in addition to other valuable products such as ethyl lactate, sodium bicarbonate, lactic acid, biogas, plant proteins etc.), algae wet recovery technology (for efficient recovery of algal lipids), etc. Most of Cellulacs bioprocesses are enabled by their proprietary SoniqueFlo technology that uses a supersonic controllable shockwave formed from the forced flow of steam or gas into a specially shaped chamber. The unique design features and capabilities of the SoniqueFlo system allow the use of 2nd and 3rd generation feedstocks for the energy-efficient production of commercial quantities of C5 and C6 sugars. The company is also part of collaborations and consortia for development of various products and technologies, such as SPLASH and FUEL4ME - EU projects for developing biobased production platforms using algae, AlgaePARC (an industry consortium for development of algal biodiesel), ALGZYM (an EU project for commercialization of a green enzyme technology for omega-3 oil production from algae).
Cellulac has 1 investor. Key investors include Integumen.
Cellulac operates through Cellulac Plc.
Yes. Cellulac was acquired by Integumen in April 2018.